Release Summary

Catabasis (NASDAQ:CATB) today announced that CAT-5571 will be presented as a potential treatment for cystic fibrosis in an oral presentation at the 40th European Cystic Fibrosis Society Conference.

Catabasis Pharmaceuticals, Inc.